ADMA Biologics Q3 revenue rises on strong ASCENIV sales
ADMA•ADMA Biologics’ Q3 2026 revenue rose 5% year over year, driven by ASCENIV sales, while adjusted basic EPS increased 44%. The company expects 2026 revenue of at least $530 million and raised its adjusted EBITDA outlook to at least $275 million.
1. Quarterly results and outlook
ADMA Biologics said Q3 2026 revenue rose 5% year over year, driven by ASCENIV sales, and adjusted basic EPS increased 44%. The company repurchased 2.7 million shares during the quarter. It expects 2026 revenue of at least $530 million and adjusted net income of at least $180 million, and raised its adjusted EBITDA outlook to at least $275 million.
2. Sales and margins
The company said ASCENIV revenue growth reflected expanding physician adoption, new patient starts and growing end-user utilization. It attributed gross margin expansion to favorable ASCENIV mix and yield-enhanced manufacturing, and said underlying BIVIGAM utilization showed signs of stabilization despite competitive pressures.
